SCA Pharma to Expand Production Facility for Compounded Sterile Medications

Construction at Windsor will allow company to add second clean room to better serve clients WINDSOR, CT. — SCA Pharma, an FDA registered Outsourcing facility, has plans to expand its sterile pharmaceutical manufacturing facility in Windsor by 40 percent. SCA has seen continued growth over the past five years and has emerged as a leading manufacturer of compounded pharmaceuticals. As a leader in the industry, SCA continually reviews all opportunities to meet the demands in the marketplace. Creating additional clean room capacity would provide another avenue for the company to increase supply in order to meet additional customer and patient needs.

SCA Pharma currently has two sterile pharmaceutical manufacturing facilities. They are located in Windsor, CT and Little Rock, AK. The planned expansion would increase the Windsor facility to approximately 150,000 square feet with the ability to add state of the art automation, compounding capability and technical employees to manufacture critical medicines.

“Ensuring that hospitals have all of the readily available sterile injectable pharmaceuticals they need to properly treat and care for the patients is more critical today than ever before,” said Milton Boyer, CEO of SCA Pharma. “The demand for SCA products continues to increase, and we are committed to meeting that need safely, efficiently and reliably. Our new construction will position us to expand our capacity and make products even more accessible to hospitals.” Boyer said construction was expected to take approximately nine months to complete.

NOTE TO REPORTERS AND EDITORS: For more information or to request an interview with Milton Boyer, please contact Natalee Kestler at nkestler@scapharma.com.